Virax has one of the most advanced clinical programs on ASX,...

Virax has one of the most advanced clinical programs on ASX, with 5 mid-stage clinical trials running under two separate INDs over next 12 months

Just compare us with IMU , they will have 1.3 to 1.4B shares post spp with maybe 4-5m cash post current spp , they have a value of 16-18m post spp at current price of 1.2c and will start their only phase 1b trial in mid 2015 .

VHL , market value just above 8m and cash just above $3m

Based on IMU alone we should be valued above 2c imo , i think we may have seen the last of the sellers , those who bought between 0.5 and 0.6 between may and october.